Zevra Therapeutics Files 8-K on Governance and Compensation
Ticker: ZVRA · Form: 8-K · Filed: Nov 20, 2025 · CIK: 1434647
| Field | Detail |
|---|---|
| Company | Zevra Therapeutics, Inc. (ZVRA) |
| Form Type | 8-K |
| Filed Date | Nov 20, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: governance, executive-compensation, filing
Related Tickers: ZEVR
TL;DR
Zevra Therapeutics (ZEVR) filed an 8-K covering board changes and executive pay. Keep an eye on governance.
AI Summary
On November 20, 2025, Zevra Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing also includes information on Regulation FD disclosures and financial statements, indicating ongoing corporate governance and financial reporting activities.
Why It Matters
This filing provides insight into the company's leadership structure and how executive compensation is being managed, which can influence investor confidence and strategic direction.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain any immediate negative financial or operational news.
Key Players & Entities
- ZEVRA THERAPEUTICS, INC. (company) — Registrant
- November 20, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 001-36913 (filing_id) — SEC File Number
- 20-5894398 (ein) — IRS Employer Identification No.
FAQ
What specific changes were made to the board of directors?
The filing indicates "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers" as an item, but the specific details of these changes are not provided in the provided text.
What are the key aspects of the compensatory arrangements mentioned?
The filing lists "Compensatory Arrangements of Certain Officers" as an item, but the specific details of these arrangements are not elaborated in the provided text.
What is the significance of the Regulation FD Disclosure item?
This indicates that the company is making public disclosures in compliance with Regulation Fair Disclosure, ensuring that material information is disseminated to all investors simultaneously.
What financial statements and exhibits are included in this filing?
The filing lists "Financial Statements and Exhibits" as an item, but the specific content of these statements and exhibits is not detailed in the provided text.
What was Zevra Therapeutics' former company name?
The filing states that the former company name was KEMPHARM, INC, with name changes occurring on May 30, 2013, and May 7, 2008.
Filing Stats: 705 words · 3 min read · ~2 pages · Grade level 11.9 · Accepted 2025-11-20 16:29:38
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share ZVRA The Nasdaq Stock Mar
Filing Documents
- d78999d8k.htm (8-K) — 27KB
- d78999dex991.htm (EX-99.1) — 6KB
- g78999g1121012905427.jpg (GRAPHIC) — 5KB
- 0001193125-25-289865.txt ( ) — 155KB
- zvra-20251120.xsd (EX-101.SCH) — 3KB
- zvra-20251120_lab.xml (EX-101.LAB) — 18KB
- zvra-20251120_pre.xml (EX-101.PRE) — 11KB
- d78999d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated November 20, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Zevra Therapeutics, Inc. Date: November 20, 2025 By: /s/ Timothy J. Sangiovanni Timothy J. Sangiovanni, CPA Senior Vice President, Finance and Corporate Controller